skip to Main Content
Clinical Operation

About service

C&R Research offers comprehensive clinical development services in Oncology. Our personnel possess extensive experience in various treatment areas, enabling us to navigate the complexities of the clinical trial environment with professionalism.

Drug Development Program Management Services

Adaptive Trial Design

Phase I/Phase IIa/Phase IIb/Phase III/Phase IV/EAP

Project Management

  • Project Strategic Planning
  • Feasibility
  • Investigator/Site Identification & Qualification
  • Pre-Study Visit
  • Investigator Meeting
  • IRB Affairs
  • Initiation Activities
  • Site Personal Training
  • Site Monitoring Activities
  • Close-Out Activities
  • Site Management
  • Project Management
  • Vendor Communication
  • IP Management
  • SAE Management
  • Document Management
  • Audit / Inspection Supporting

Central Monitoring Clinical Trails (Data Review)

  • Critical Data Quality
  • Protocol Compliance
  • Site Data Quality Matrix
  • Other Data Related Issues

Clinical Data Management Analysis and Reporting

Drug Life Cycle Management

Vast experience and expertise across a broad range of therapeutic areas

To this date, C&R Research has conducted more than 100 oncology clinical trials of 25,000 patients at 1,000 sites, with extensive experience in 25 therapeutic areas in oncology. In particular, C&R Research’s experts are well-versed in hematology, oncology, solid tumors, and cell/gene therapies and helps clients conduct successful clinical trials.

Global-level oncology services in clinical trial

C&R Research has actively assisted new drug development process across a broad range of oncology areas in all phases of clinical trials, ranging from Phase I to post-approval and expanded access program (EAP). Using the global standard formats, such as CDISC (Global Data Standards), SDTM (CDISC-Data Tabulation), ADaM (CDISC-Data Analysis), and E2B (ICH Clinical Safety Data Management Guide), C&R Research is engaged in the pivotal and supportive clinical trials process that may lead to final approval of global drug regulatory agencies.

Back To Top